Site 'Tertiary' Navigation:

Page 'Breadcrumb' Navigation:

Press Releases

 
Press Releases
  Date Title and Summary View
Apr 24, 2017
Top-line data from the studies expected in June 2017 SALT LAKE CITY, April 24, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. ...
Mar 28, 2017
SALT LAKE CITY, March 28, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, Pr...
Mar 14, 2017
SALT LAKE CITY, March 14, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, Pr...
Mar 6, 2017
SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and opera...
Mar 6, 2017
SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and C...
Feb 15, 2017
SALT LAKE CITY, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company focused on developing innovative oral treatment alte...
Jan 9, 2017
Critical Phase 3 study design input received from U.S. Food and Drug Administration ("FDA"): Agreed to a randomized open-label, two-arm clinical study to include a LPCN 1107 arm and a comparator intramuscular ("IM") arm with treatment up to 23 weeksProvided positive feedback on the proposed 80...
Jan 5, 2017
SALT LAKE CITY, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced plans to initiate a dosing flexib...
Dec 5, 2016
SALT LAKE CITY, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced it plans to initiate a dosing valid...
Nov 8, 2016
SALT LAKE CITY, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results f...
Page:
1
... NextLast
= add release to Briefcase